Resverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture Extension
Resverlogix Corp. (TSX: RVX) held its Annual & Special Meeting of Shareholders on July 31, 2024, in Calgary, Alberta. Shareholders elected four Board members and approved all resolutions outlined in the Notice of Meeting and Management Information Circular. The voting results showed strong support for all directors, with approval rates ranging from 95.11% to 95.91%.
Additionally, Resverlogix announced the closing of a two-year extension of its US$6.0 million secured debenture with Shenzhen Hepalink Pharmaceutical Group Co., This extension provides the company with continued financial stability. The Information Circular is available on SEDAR and the Resverlogix website, and a webcast archive of the executive presentation is accessible online.
Resverlogix Corp. (TSX: RVX) ha tenuto l'Assemblea Annuale e Straordinaria degli Azionisti il 31 luglio 2024, a Calgary, Alberta. Gli azionisti hanno eletto quattro membri del Consiglio e approvato tutte le risoluzioni delineate nella Notifica di Riunione e nel Circolare Informativa della Direzione. I risultati delle votazioni hanno mostrato un forte sostegno per tutti i direttori, con percentuali di approvazione che variavano tra il 95,11% e il 95,91%.
Inoltre, Resverlogix ha annunciato la chiusura di un allungamento di due anni del suo debito garantito da 6,0 milioni di dollari USA con Shenzhen Hepalink Pharmaceutical Group Co. Questo allungamento offre all'azienda una continua stabilità finanziaria. La Circolare Informativa è disponibile su SEDAR e sul sito web di Resverlogix, e un'archivio della presentazione esecutiva è accessibile online.
Resverlogix Corp. (TSX: RVX) llevó a cabo su Asamblea Anual y Extraordinaria de Accionistas el 31 de julio de 2024, en Calgary, Alberta. Los accionistas eligieron a cuatro miembros de la Junta y aprobaron todas las resoluciones detalladas en el Aviso de Reunión y en el Circular de Información de la Administración. Los resultados de la votación mostraron un fuerte apoyo a todos los directores, con tasas de aprobación que variaban entre 95,11% y 95,91%.
Adicionalmente, Resverlogix anunció el cierre de una prórroga de dos años de su bono garantizado de 6,0 millones de dólares estadounidenses con Shenzhen Hepalink Pharmaceutical Group Co. Esta extensión proporciona a la empresa una estabilidad financiera continua. El Circular de Información está disponible en SEDAR y en el sitio web de Resverlogix, y un archivo de la presentación ejecutiva está accesible en línea.
Resverlogix Corp. (TSX: RVX)는 2024년 7월 31일 앨버타주 캘거리에서 주주 연례 및 특별 회의를 개최했습니다. 주주들은 이사회 구성원 네 명을 선출하고 회의 통지 및 경영 정보 순환에 명시된 모든 결의안을 승인했습니다. 투표 결과는 모든 이사에 대한 강한 지지를 보여주었으며, 승인율은 95.11%에서 95.91%까지 다양했습니다.
또한, Resverlogix는 Shenzhen Hepalink Pharmaceutical Group Co.와의 600만 달러 미국의 담보부 사채 의 2년 연장이 완료되었다고 발표했습니다. 이 연장은 회사에 지속적인 재정적 안정성을 제공합니다. 정보 순환은 SEDAR 및 Resverlogix 웹사이트에서 이용 가능하며, 경영진 발표의 웹캐스트 아카이브도 온라인에서 접근할 수 있습니다.
Resverlogix Corp. (TSX: RVX) a tenu son Assemblée Annuelle et Spéciale des Actionnaires le 31 juillet 2024 à Calgary, Alberta. Les actionnaires ont élu quatre membres du Conseil d'administration et approuvé toutes les résolutions décrites dans l'Avis de Réunion et le Circulaire d'Information de la Direction. Les résultats du vote ont montré un fort soutien pour tous les directeurs, avec des taux d'approbation variant de 95,11 % à 95,91 %.
De plus, Resverlogix a annoncé la clôture d'une extension de deux ans de son obligation garantie de 6,0 millions de dollars américains avec Shenzhen Hepalink Pharmaceutical Group Co. Cette extension offre à l'entreprise une stabilité financière continue. Le Circulaire d'Information est disponible sur SEDAR et sur le site Web de Resverlogix, et un archive de la présentation exécutive est accessible en ligne.
Resverlogix Corp. (TSX: RVX) hielt am 31. Juli 2024 in Calgary, Alberta, seine Jahres- und Sonderversammlung der Aktionäre ab. Die Aktionäre wählten vier Mitglieder des Vorstands und genehmigten alle in der Einladung zur Sitzung und im Informationsrundschreiben der Geschäftsführung dargelegten Beschlüsse. Die Abstimmungsergebnisse zeigten eine starke Unterstützung für alle Direktoren, wobei die Zustimmungsraten zwischen 95,11% und 95,91% lagen.
Zusätzlich kündigte Resverlogix den Abschluss einer zwei Jahre langen Verlängerung seiner 6,0 Millionen USD sicheren Anleihe mit Shenzhen Hepalink Pharmaceutical Group Co. an. Diese Verlängerung bietet dem Unternehmen eine anhaltende finanzielle Stabilität. Der Informationsrundschreiben ist auf SEDAR und der Website von Resverlogix verfügbar, und ein Archiv der Präsentation der Geschäftsführung ist online zugänglich.
- High shareholder approval rates for all directors (95.11% to 95.91%)
- Successful extension of US$6.0 million secured debenture for two years
- None.
Calgary, Alberta--(Newsfile Corp. - July 31, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual & Special Meeting of Shareholders (the "Meeting") in Calgary, Alberta.
During business proceedings at the Meeting, shareholders elected four (4) Board members until the next annual meeting. The voting results of shares represented at the Meeting for individual directors were as follows:
| Votes For | Votes Withheld | Percent For | Percent Withheld | |
| Donald J. McCaffrey | 131,554,931 | 6,759,498 | ||
| Kelly McNeill | 132,370,485 | 5,943,944 | ||
| Siu Lun (Dicky) To | 132,663,593 | 5,650,836 | ||
| Kenneth Zuerblis | 132,354,299 | 5,960,130 |
Resverlogix shareholders approved all resolutions outlined in the Notice of Meeting and Management Information Circular dated June 14, 2024 (the "Information Circular"). The Information Circular is available on SEDAR at www.sedar.com, and on the Resverlogix website at www.resverlogix.com.
A webcast archive of the executive presentation portion of the Meeting will be available HERE.
Resverlogix also announced that it has closed the previously-announced two year extension of its US
About Resverlogix
Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.
Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions - altered by serious illnesses such as cardiovascular disease - back to a healthier state.
The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions.
Resverlogix has partnered with EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, to support the rapid commercialization of apabetalone for cardiovascular disease, post COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX).
Follow us on:
- Twitter: @Resverlogix_RVX
- LinkedIn: https://www.linkedin.com/company/resverlogix-corp-/
Forward Looking Statements:
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts", and other similar expressions. In particular, this news release includes forward looking information related to the potential role of apabetalone in the treatment of patients with cardiovascular disease, post COVID-19 conditions, pulmonary arterial hypertension, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information please contact:
Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/218479
FAQ
What were the voting results for Resverlogix's 2024 Annual & Special Meeting of Shareholders?
Has Resverlogix (TSX: RVX) extended its secured debenture?
Where can I find the Information Circular for Resverlogix's 2024 shareholder meeting?
Is there a webcast available for Resverlogix's 2024 Annual & Special Meeting of Shareholders?
